Plasma is a rich source of biomarkers with clinical relevance. However, the wide dynamic
range of protein concentration hinders the detection of low abundance proteins. Plasma …

The complement cascade is a major component of the immune defence against infection,
and there is increasing evidence for a role of dysregulated complement in major psychiatric …

Schizophrenia is an incurable neuropsychiatric disorder managed mostly by treatment of the
patients with antipsychotics. However, the efficacy of these drugs has remained only low to …

Abstract Background Excessive C4A-gene expression may result in increased microglia-
mediated synaptic pruning. As C4A overexpression is observed in schizophrenia spectrum …

A better understanding of the proteome profile after bipolar disorder (BD) and schizophrenia
(SCZ) treatment, besides monitoring disease progression, may assist on the development of …

There are no validated biomarkers for schizophrenia (SCZ), a disorder linked to neural
network dysfunction. We demonstrate that collapsin response mediator protein-2 (CRMP2) …

Disrupted-in-schizophrenia 1 (DISC1) is a key protein involved in behavioral processes and
various mental disorders, including schizophrenia and major depression. A transgenic rat …

Introduction. The mechanism by which metabolic syndrome occurs in schizophrenia is not
completely known; however, previous work suggests that changes in DNA methylation may …

Vitamin D binding protein (VDBP) serves as a key transporter protein responsible for binding
and delivering vitamin D and its metabolites to target organs. VDBP plays a crucial part in …

Background Antipsychotic treatment-related alterations of cortical thickness (CT) and clinical
symptoms have been previously corroborated, but less is known about whether the changes …